Metabolic dysfunction–associated steatotic liver disease (MASLD) and its inflammatory form, MASH, are now recognized as core metabolic diseases rather than isolated liver disorders. They are tightly linked to insulin resistance, obesity, type 2 diabetes, and dyslipidaemia conditions traditionally managed by endocrinologists. With emerging therapies targeting metabolic pathways (e.g., GLP-1 receptor agonists, dual incretins, insulin sensitizers), endocrinology is increasingly central to the prevention, diagnosis, and treatment of MASLD/MASH, bridging metabolic and hepatic care. Join us for an informative session titled “MASLD/MASH - Endocrinology’s Expanding Territory,” presented by the renowned endocrinologist Dr.
Vinod K. Abichandani , on 23 rd December 2025 at 8:30 PM IST onwards . Stay tuned! ##Disclaimer## The content provided on Docplexus is intended for educational purposes only.…
